An update is available for this article. Background: The prevalence of osteoporosis is
increasing in the United States. Purpose: To evaluate low bone mass and osteoporosis …

This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of …

An update is available for this article. Description: This guideline updates the 2017 American
College of Physicians (ACP) recommendations on pharmacologic treatment of primary …

PURPOSE To provide guidance regarding best practices in the prevention and
management of medication-related osteonecrosis of the jaw (MRONJ) in patients with …

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A
Clinical Practice Guideline Update From the American College of Physicians | Annals of Internal …

Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This
ASBMR report provides guidance on BP therapy duration with a risk‐benefit perspective …

Background: Osteoporosis is a major contributor to the propensity to fracture among older
adults, and various pharmaceuticals are available to treat it. Purpose: To update a review …

Background Bisphosphonates are specific inhibitors of osteoclastic activity and used in the
treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be …

Aims The aim of this study is to gain a better understanding of the overall incidence and risk
of osteonecrosis of the jaw (ONJ) in cancer patients receiving denosumab. Methods We …

Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with
antiresorptive treatment. There is little evidence regarding the incidence of ONJ among …